Abstract:A novel style of versatile nano‐proteolysis targeting chimera is constructed by the incorporation of the BRD4 degrader dBET6, which aims to target both lung cancer cells and M2 tumor‐associated macrophages (TAMs) which favors the tumor‐promoting microenvironment. Specific degradation of BRD4 leads to substantial cell apoptosis of both lung cancer cells and TAMs, thereby remodeling the tumor microenvironment, which in turn, renders tumor shrinkage. This work proposes a novel approach for specifically delivering the BRD4 degrader to regress cancers. Recent evidence has indicated that overexpression of the epigenetic reader bromodomain‐containing protein 4 (BRD4) contributes to a poor prognosis of lung cancers, and the suppression of its expression promotes cell apoptosis and leads to tumor shrinkage. Proteolysis targeting chimera (PROTAC) has recently emerged as a promising therapeutic strategy with the capability to precisely degrade targeted proteins. Herein, a novel style of versatile nano‐PROTAC (CREATE (CRV‐LLC membrane/DS‐PLGA/dBET6)) is developed, which is constructed by using a pH/GSH (glutathione)‐responsive polymer (disulfide bond‐linked poly(lactic‐co‐glycolic acid), DS‐PLGA) to load BRD4‐targeted PROTAC (dBET6), followed by the camouflage with engineered lung cancer cell membranes with dual targeting capability. Notably, CREATE remarkably confers simultaneous targeting ability to lung cancer cells and tumor‐associated macrophages (TAMs). The pH/GSH‐responsive design improves the release of dBET6 payload from nanoparticles to induce pronounced apoptosis of both cells, which synergistically inhibits tumor growth in both subcutaneous and orthotopic tumor‐bearing mouse model. Furthermore, the efficient tumor inhibition is due to the direct elimination of lung cancer cells and TAMs, which remodels the tumor microenvironment. Taken together, the results elucidate the construction of a versatile nano‐PROTAC enables to eliminate both lung cancer cells and TAMs, which opens a new avenue for efficient lung cancer therapy via PROTAC.

Targeted delivery of PROTAC-based prodrug activated by bond-cleavage bioorthogonal chemistry for microneedle-assisted cancer therapy

PROTACs: an Emerging Targeting Technique for Protein Degradation in Drug Discovery

Tumor-targeted PROTAC prodrug nanoplatform enables precise protein degradation and combination cancer therapy

A region-confined PROTAC nanoplatform for spatiotemporally tunable protein degradation and enhanced cancer therapy

Bioorthogonal PROTAC Prodrugs Enabled by On-Target Activation

Radiotherapy-Triggered Proteolysis Targeting Chimera Prodrug Activation in Tumors

Radiation Responsive PROTAC Nanoparticles for Specific Tumor Proteolysis Enhanced Radiotherapy

[Advances in targeted delivery of proteolysis targeting chimeras in cancer therapy]

Engineered bioorthogonal POLY-PROTAC nanoparticles for tumour-specific protein degradation and precise cancer therapy

PROTAC: An Effective Targeted Protein Degradation Strategy for Cancer Therapy

Discovery of intracellular self-assembly protein degraders driven by tumor-specific activatable bioorthogonal reaction

Stimuli-activatable PROTACs for precise protein degradation and cancer therapy

Controlled bioorthogonal activation of Bromodomain-containing protein 4 degrader by co-delivery of PROTAC and Pd-catalyst for tumor-specific therapy

Versatile Nano‐PROTAC‐Induced Epigenetic Reader Degradation for Efficient Lung Cancer Therapy

Proteolysis-targeting chimera (PROTAC) for targeted protein degradation and cancer therapy

A PROTAC Augmenter for Photo‐driven Pyroptosis in Breast Cancer

PROTAC-biomacromolecule conjugates for precise protein degradation in cancer therapy: A review

Hydrogen Peroxide-Inducible PROTACs for Targeted Protein Degradation in Cancer Cells

MicroRNA‐Triggered Programmable DNA‐Encoded Pre‐PROTACs for Cell‐Selective and Controlled Protein Degradation

Recent Advances in Pro-PROTAC Development to Address On-Target Off-Tumor Toxicity.

Novel strategies and promising opportunities for targeted protein degradation: An innovative therapeutic approach to overcome cancer resistance